Organic Pressurized Fluid Patents (Class 424/45)
  • Patent number: 9241876
    Abstract: The preparation method includes the following steps: dissolving aripiprazole in an acidic solution having an acidifier so as to obtain a medicament having acidic solution; then, performing a wet granulation on or preparing a suspension with the obtained medicament having acidic solution, an alkalizer, and an excipient so as to obtain the aripiprazole medicament formulation; the excipient comprising an antioxidant. The aripiprazole medicament formulation obtained through the preparation method has a significantly reduced amount of related substances, great solubility, great stability, high bioavailability, reduced individual differences, and enhanced wettability and content uniformity of insoluble medicaments.
    Type: Grant
    Filed: June 26, 2012
    Date of Patent: January 26, 2016
    Assignee: SHANGHAI ZHONGXI PHARMACEUTICAL CORPORATION
    Inventors: Siji Zheng, Xiaoyi Liu, Linyong Fu, Bo Tan, Min Zhou
  • Patent number: 9226509
    Abstract: The present invention relates to the use of R—OH alcohols as phagodeterrents, and to a method for treating plants infested with aphids which comprises the administration of these R—OH alcohols.
    Type: Grant
    Filed: May 14, 2012
    Date of Patent: January 5, 2016
    Assignee: Consiglio Nazionale Delle Ricerche
    Inventors: Maria Agnese Sabatini, Sonia Ganassi, Claudio Altomare, Mara Favilla, Antonio Evidente, Anna Andolfi
  • Patent number: 9220717
    Abstract: Methods relating to local injections of corticosteroids are provided. More specifically intralesional injections of corticosteroids and preferably Triamcinolone and its derivatives are suitable to produce medicaments to be injected in the subcutaneous fat at deep levels to provoke cosmetic lipoatrophy of small fat deposits on the face and body.
    Type: Grant
    Filed: March 2, 2010
    Date of Patent: December 29, 2015
    Inventor: Doris Hexsel
  • Patent number: 9205100
    Abstract: Disclosed herein are therapeutic methods for treating lung diseases, disorders and injury in a mammal, including treatment of acute respiratory distress syndrome (ARDS), acute lung injury, pulmonary fibrosis (idiopathic), bleomycin induced pulmonary fibrosis, mechanical ventilator induced lung injury, chronic obstructive pulmonary disease (COPD), chronic bronchitis, emphysema, bronchiolitis obliterans after lung transplantation and lung transplantation-induced acute graft dysfunction, including treatment, prevention or prevention of progression of primary graft failure, ischemia-reperfusion injury, reperfusion injury, reperfusion edema, allograft dysfunction, pulmonary reimplantation response, bronchiolitis obliterans after lung transplantation and/or primary graft dysfunction (PGD) after organ transplantation, in particular in lung transplantation, comprising downregulating the TLR2 gene or both the TLR2 gene and TLR4 gene.
    Type: Grant
    Filed: March 1, 2012
    Date of Patent: December 8, 2015
    Assignees: Quark Pharmaceuticals, Inc., Washington University
    Inventors: Andrew E. Gelman, Elena Feinstein, Svetlana Adamsky, Igor Mett, Hagar Kalinski, Sharon Avkin-Nachum
  • Patent number: 9199870
    Abstract: A high-surface quality glass sheet is formed using a roll-to-roll glass soot deposition and sintering process. The glass sheet formation involves providing glass soot particles, depositing a first fraction of the glass soot particles on a deposition surface to form a supported soot layer, electrostatically attracting and collecting a second fraction of the glass soot particles onto a surface of a charged plate, removing the soot layer from the deposition surface to form a soot sheet, and heating at least a portion of the soot sheet to sinter the glass soot particles to form a glass sheet.
    Type: Grant
    Filed: May 22, 2012
    Date of Patent: December 1, 2015
    Assignee: CORNING INCORPORATED
    Inventors: Daniel Warren Hawtof, Brenton Allen Noll, Srinivas Vemury
  • Patent number: 9192654
    Abstract: The invention relates to the use of the PAT nonapeptide in the manufacture of a drug for preventing or treating a neurodegenerative disease such as Alzheimer's disease. The parenteral route of administration is preferable, including the subcutaneous, intraperitoneal, intravenous or intranasal routes. The invention also relates to an injectable formulation containing the PAT nonapeptide which can be administered to patients suffering from a neurodegenerative disease such as Alzheimer's disease.
    Type: Grant
    Filed: July 11, 2011
    Date of Patent: November 24, 2015
    Assignee: CLL PHARMA
    Inventors: Jamal Temsamani, Claude Laruelle
  • Patent number: 9186320
    Abstract: This invention relates to a galenical gel formulation for nasal administration of neurotransmitters/neuromodulators such as dopamine, serotonin or pregnenolone and progesterone. The special lipophilic or partly lipophilic system of the invention leads to high bioavailability of the active ingredient in plasma and brain caused by sustained serum levels and/or direct or partly direct transport from nose to the brain.
    Type: Grant
    Filed: July 30, 2011
    Date of Patent: November 17, 2015
    Assignee: MATTERN PHARMA AG
    Inventor: Claudia Mattern
  • Patent number: 9188581
    Abstract: The present invention relates to asthma. Particularly, the present invention relates to clinical screening, diagnosis, prognosis, therapy and prophylaxis, as well as for drug screening and drug development for the treatment of asthma. The present invention relates to a new paradigm in diagnosing, screening, and treating asthma by affecting airway epithelial synchronization.
    Type: Grant
    Filed: April 6, 2011
    Date of Patent: November 17, 2015
    Assignee: The Children's Research Instiute
    Inventors: Robert J. Freishtat, Eric P. Hoffman
  • Patent number: 9180109
    Abstract: Use of glyceryl trinitrate (GTN) for treating traumatic edemas.
    Type: Grant
    Filed: August 3, 2011
    Date of Patent: November 10, 2015
    Assignee: G. POHL-BOSKAMP GMBH & CO. KG
    Inventor: Marianne Boskamp
  • Patent number: 9181577
    Abstract: The present invention provides compositions and methods for detection, diagnosis, treatment and/or prevention of chronic pelvic pain syndrome. In particular, the present invention provides biomarkers of chronic pelvic pain syndrome (e.g., mast cell markers (e.g., tryptase)), and/or inhibition of mast cell function (e.g. inhibition of MCP-1 and/or MIP-1?) to treat or prevent chronic pelvic pain syndrome.
    Type: Grant
    Filed: November 19, 2013
    Date of Patent: November 10, 2015
    Assignee: Northwestern University
    Inventors: Praveen Thumbikat, Anthony J. Schaeffer, Joseph Done, David J. Klumpp, Charles Rudick
  • Patent number: 9167813
    Abstract: A substantially surface active agent-free foamable composition which includes short-chain alcohol, water, polymer, fatty alcohol or fatty acid or a combination of fatty alcohol and fatty acid and propellant. A substantially surface active agent-free foamable composition which includes, water, polymer, fatty alcohol or fatty acid and propellant. A method of treatment using a substantially surface active agent-free foamable compositions.
    Type: Grant
    Filed: January 27, 2012
    Date of Patent: October 27, 2015
    Assignee: Foamix Pharmaceuticals Ltd.
    Inventors: Dov Tamarkin, Enbal Ziv, Yohan Hazot, David Schuz
  • Patent number: 9168282
    Abstract: Disclosed is a method of treating pain. The method includes administering a lecithin as an active ingredient to a mammal to treat the pain, wherein the pain is caused by at least one of herpes zoster, post-herpetic neuralgia, and diabetic neuropathic pain. The method further includes administering at least one selected from the group consisting of vegetable gel, a vegetable resin, and a synthetic resin, wherein the vegetable gel, vegetable resin, and synthetic resin is selected from the group consisting of aloe gel; a seaweed extract selected from the group consisting of kelp extract, agar extract, and Fucoidan; and a mixture thereof.
    Type: Grant
    Filed: September 25, 2013
    Date of Patent: October 27, 2015
    Assignee: DONGKOOK PHARMACEUTICAL CO., LTD.
    Inventors: Jae-Hoon Jung, Hyung-Ryong Moon
  • Patent number: 9155699
    Abstract: In one aspect, the invention is related to a method of treating a patient with Parkinson's disease, the method including administering to the respiratory tract of the patient particles that include more than about 90 weight percent (wt %) of levodopa. The particles are delivered to the patient's pulmonary system, preferably to the alveoli or the deep lung.
    Type: Grant
    Filed: October 17, 2013
    Date of Patent: October 13, 2015
    Assignee: Civitas Therapeutics, Inc.
    Inventors: Blair C. Jackson, David J. Bennett, Raymond T. Bartus, Dwaine F. Emerich
  • Patent number: 9138407
    Abstract: Provided is an inhalatory pharmaceutical composition that comprises a drug, a soluble excipient and a surfactant, wherein the soluble excipient is present in an amount between 10% and less than 100% by weight; and the solid excipient forms a solid matrix in which the drug is dispersed; the weight ratio between the surfactant and drug is between 0.01 and 10; the particle size of at least 50% of the particles of the powder is below 5 ?m; the bulk density db of the powder is between 0.1 and 0.3 g/cc; the tapped density dt of the powder is between 0.15 and 0.7 g/cc and the ratio db/dt is between 0.2 and 0.65. Also provided is the method for fabricating the composition.
    Type: Grant
    Filed: October 20, 2006
    Date of Patent: September 22, 2015
    Assignee: Eratech S.R.L.
    Inventors: Giovanni Caponetti, Loretta Maggi, Laura Zanellotti, Cristina Veneziani
  • Patent number: 9138409
    Abstract: A stable, high VOC, single phase, non-aqueous liquid aerosol composition having enhanced dispersion based on reduced particle size and increased evaporation rate to result in improved active ingredient dispersion, slower settling in air and less residue on surfaces. The composition includes at least one hydrocarbon propellant, at least one active ingredient and a solvent blend. The solvent blend includes at least one low volatility solvent and at least one high volatility solvent wherein each has a defined vapor pressure and Hansen solubility parameter. The composition upon dispersion as a spray has an aerosol particle size of less than 30 microns.
    Type: Grant
    Filed: May 31, 2013
    Date of Patent: September 22, 2015
    Assignee: S.C. Johnson & Son, Inc.
    Inventors: Peter N. Nguyen, John R. Wietfeldt, Yemi S. Bullen, Francis J. Randall, Randy C. Yuhas
  • Patent number: 9125872
    Abstract: A polyethylene glycol (PEG) aerogel particles having an average particle diameter not substantially above about 2?, a volumetric porosity of greater than about 50%, and pore sizes capable of retaining drug molecules. A method for preparing such polyethylene glycol (PEG) aerogel particles includes initiating a catalyzed reaction using a catalyst of PEG forming ingredients to form PEG particles; partially drying the formed PEG particles under conditions to control pore size; and subjecting the partially dried formed PEG particles to CO2 supercritical extraction for form the PEG aerogel particles. Drug molecules include chemotherapeutic agents. The surface of the PEG aerogel particles are reactable with a variety of agents, for example, to selectively target tumors, protects irreversible damage to labile proteins, and protects degradation of sensitive drugs with subsequent loss of biological efficacy.
    Type: Grant
    Filed: October 12, 2010
    Date of Patent: September 8, 2015
    Inventor: Yosry A. Attia
  • Patent number: 9095544
    Abstract: The invention relates to a composition containing cetrimide suitable for cleaning inflamed or non-inflamed ears of animals, preferably of companion animals such as dogs and cats. The composition further comprises one or more carriers, such as for example wetting agents and humectants.
    Type: Grant
    Filed: December 21, 2011
    Date of Patent: August 4, 2015
    Assignee: Boehringer Ingelheim Vetmedica GmbH
    Inventors: Joachim Karle, Reinhard Seffner, Horst Sollinger
  • Patent number: 9078923
    Abstract: The present invention relates to a stable fixed dose aqueous pharmaceutical composition (e.g., contained in a container) for nasal administration to a human, comprising mometasone or its salt, olopatadine or its salt. The composition may further include a hydrocolloid. The invention also relates to a process for preparing the pharmaceutical composition, and the use of the pharmaceutical composition in the treatment of rhinitis in a subject.
    Type: Grant
    Filed: September 11, 2014
    Date of Patent: July 14, 2015
    Assignee: GLENMARK PHARMACEUTICALS LIMITED
    Inventors: Ulhas Dhuppad, Ashok Katkurwar, Yashwant Gupta, Rajesh Ankam, Chandrakant Dhatrak
  • Patent number: 9072683
    Abstract: The present invention is directed to the use of xanthan gum, particularly heat treated xanthan gum, as a fixative in hair cosmetic compositions. Xanthan gum is advantageous in that it may be used with other hair fixatives and provides rheology modifying and other properties including excellent stiffness, gloss, dry comb, wet comb, non-flake, anti-static, feel and high humidity curl retention.
    Type: Grant
    Filed: July 18, 2002
    Date of Patent: July 7, 2015
    Assignee: AKZO NOBEL N.V.
    Inventors: Hongjie Cao, Gary T. Martino, Paul H. Richardson
  • Patent number: 9072667
    Abstract: A substantially surface active agent-free and substantially polymeric agent-free foamable composition which includes short-chain alcohol, water, fatty alcohol or fatty acid or a combination of fatty alcohol and fatty acid and propellant. A substantially surface active agent-free and substantially polymeric agent-free foamable composition which includes water, fatty alcohol or fatty acid and propellant. A method of treatment using a substantially surface active agent-free and substantially polymeric agent-free foamable composition.
    Type: Grant
    Filed: January 27, 2012
    Date of Patent: July 7, 2015
    Assignee: Foamix Pharmaceuticals Ltd.
    Inventors: Dov Tamarkin, Enbal Ziv, Yohan Hazot, David Schuz
  • Patent number: 9050253
    Abstract: The invention relates to stable oleaginous cosmetic or therapeutic foam compositions containing certain active agents, having unique therapeutic properties and methods of treatment using such compositions. The foamable composition includes at least one solvent selected from a hydrophobic solvent, a silicone oil, an emollient, a co-solvent, and mixtures thereof, wherein the solvent is present at a concentration of about 70% to about 96.5% by weight of the total composition, at least a non-ionic surface-active agent at a concentration of about 0.1% to less than about 10% by weight of the total composition; at least one gelling agent at a concentration of about 0.1% to about 5% by weight of the total composition; a therapeutically effective amount of at least one active agent; and at least one liquefied or compressed gas propellant, at a concentration of about 3% to about 25% by weight of the total composition.
    Type: Grant
    Filed: April 7, 2014
    Date of Patent: June 9, 2015
    Assignee: Foamix Pharmaceuticals Ltd.
    Inventors: Dov Tamarkin, Doron Friedman, Meir Eini, Alex Besonov
  • Publication number: 20150147280
    Abstract: An azeotrope-like mixture consisting essentially of chlorotrifluoropropene and at least one component selected from the group consisting of a C1-C3 alcohol, a C5-C6 hydrocarbon, a halogenated hydrocarbon, methylal, methyl acetone, water, nitromethane, and combinations thereof.
    Type: Application
    Filed: January 30, 2015
    Publication date: May 28, 2015
    Inventors: Rajat Basu, Leslie Bement, Kane Cook, Ryan Hulse, Gary Knopeck, Hang T. Pham, Rajiv R. Singh, David J. Williams
  • Patent number: 9040024
    Abstract: An air treating composition for eliminating airborne malodors and/or sanitizing air in combination with a spray valve and actuator and spray performance parameters providing maximum dispersion of the composition is disclosed. The particles of the composition are small so that the active component is dispersed into air as a fine dispersion to provide more contact with malodors and to provide quick absorption of malodors and/or bacteria. The particle size of the composition is controlled through the valve and actuator dimensions, as well as the formulation requirements of the composition. The air treating composition includes water, a low molecular weight polyol, and a propellant. The composition may also include one or more adjuvants such as an emulsifier, a co-solvent, a fragrance, a corrosion inhibitor, a pH adjusting agent and the like.
    Type: Grant
    Filed: March 5, 2013
    Date of Patent: May 26, 2015
    Assignee: S.C. Johnson & Son, Inc.
    Inventors: Maciej K. Tasz, Richard S. Valpey, III, Paul A. Clark
  • Patent number: 9028854
    Abstract: A pesticidal composition comprising 4-phenoxyphenyl 2-(2-pyridyloxy)propyl ether; a hydrophobic organic solvent capable of dissolving 0.1-fold by weight of 4-phenoxyphenyl 2-(2-pyridyloxy)propyl ether at 0° C.; polyvinyl alcohol; a nonionic surfactant selected from the group consisting of alkoxylated castor oil, alkoxylated hydrogenated castor oil and alkoxylated hydrogenated castor oil fatty acid ester; and water, is excellent in storage stability.
    Type: Grant
    Filed: December 13, 2005
    Date of Patent: May 12, 2015
    Assignee: Sumitomo Chemical Company, Limited
    Inventor: Toshiyuki Tanedani
  • Publication number: 20150118164
    Abstract: A waterless foamable pharmaceutical composition suitable for external administration is disclosed. The composition includes a foamable carrier least one liquefied or compressed gas propellant. The foamable carrier includes at least one liquid oil; at least one silicone and at least one least one stabilizing agent; wherein the stabilizing agent selected from the group consisting of about 0.01% to about 25% by weight of at least one surface-active agent alone or on combination with a foam adjuvant; and about 0% to about 5% by weight of at least one polymeric agent alone or on combination with a foam adjuvant; and mixtures thereof. Pharmaceutical compositions comprising active agents, methods for their preparation, propellants suitable for use with the carriers and uses thereof are further described.
    Type: Application
    Filed: October 2, 2014
    Publication date: April 30, 2015
    Inventors: Dov Tamarkin, Helena Shifrin, Rita Keynan, Enbal Ziv, Tal Berman, David Schuz, Elana Gazal
  • Patent number: 9011923
    Abstract: The present invention relates to suspension formulations, especially those for delivering a pharmaceutically active agent in aerosol form using a spray or aerosol device, such as a pressurized metered dose inhaler (pMDI). The formulations may be for pulmonary, nasal, buccal or topical administration, but are preferably for pulmonary inhalation.
    Type: Grant
    Filed: February 2, 2009
    Date of Patent: April 21, 2015
    Assignees: Innovata Biomed Limited, Vectura Limited
    Inventors: David Andrew Lewis, Christina Alexandra Keeble, Nicola Kim Whitfield, Tanya Church
  • Patent number: 9011882
    Abstract: The present disclosure provides DDAH modulators. Thus, the present disclosure provides a method of treating a patient suffering from a disorder characterized by excessive NO production and/or elevated DDAH activity, the method comprising administering to said patient an effective amount of a compound of one of formulae I-X. The present disclosure also provides a pharmaceutical composition comprising a compound of one of formulae I-X.
    Type: Grant
    Filed: February 13, 2013
    Date of Patent: April 21, 2015
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Yohannes T. Ghebremariam, John P. Cooke
  • Patent number: 9005584
    Abstract: Spray compositions are formulated with powders (e.g. corn starch) which improve skin feel, and also have a hydrophobically modified oxide additive (e.g. modified silica) to reduce the incidence of can/bottle clogging and sedimentation caused by the powder. The oxide is a mixed hydrophobic/hydrophilic oxide such as hydrophobicly modified fumed silica (e.g. silica dimethyl silylate). In one embodiment DEET can be delivered by such formulations.
    Type: Grant
    Filed: June 8, 2012
    Date of Patent: April 14, 2015
    Assignee: S.C. Johnson & Son, Inc.
    Inventor: John S. Trent
  • Publication number: 20150093338
    Abstract: There is provided compositions and methods for the treatment of respiratory conditions such as pulmonary hypertension and sickle-cell disease in a patient in need thereof. The composition and method are for treating a patient in need thereof by inhalation of a composition containing amino acid ester compounds comprising at least one nitric oxide releasing group and pharmaceutical salts thereof.
    Type: Application
    Filed: October 8, 2014
    Publication date: April 2, 2015
    Inventor: Michael Farber
  • Patent number: 8992889
    Abstract: A freshening composition having a malodor control component, about 1% to about 5% of low molecular weight monohydric alcohols, and an aqueous carrier are provided. The composition is essentially free of any material that would soil or stain fabric. The composition may be delivered to fabrics and/or air. The malodor control component may include an effective amount of volatile aldehydes and/or an acid catalyst.
    Type: Grant
    Filed: April 7, 2011
    Date of Patent: March 31, 2015
    Assignee: The Procter & Gamble Company
    Inventors: Ricky Ah-Man Woo, Steven Anthony Horenziak, Rhonda Jean Jackson, Zaiyou Liu, Michael-Vincent Nario Malanyaon, Jason John Olchovy, Christine Marie Readnour
  • Patent number: 8992890
    Abstract: The invention discloses pharmaceutical compositions in the form of a dusting powder or dry spray, possessing a high absorbent capacity, painkilling activity and wound-healing action, which compositions consist of croscarmellose sodium, a non-steroidal anti-inflammatory drug (NSAID) and hyaluronic acid, and optionally also contain other pharmacologically active substances and/or excipients. The compositions disclosed herein are suitable for use in the treatment of skin lesions wherein the presence of exudate limits wound healing and causes pain; they are therefore particularly suitable for chronic ulcerous skin lesions of various origins and burns.
    Type: Grant
    Filed: February 13, 2012
    Date of Patent: March 31, 2015
    Assignee: Fidia Farmaceutici S.p.A.
    Inventors: Andrea Pastorello, Devis Galesso, Fabio Bettella
  • Publication number: 20150086489
    Abstract: A pharmaceutical composition comprising: (a) a compound of formula 1 wherein: n is 1 or 2; R1 is hydrogen, halogen, C1-4-alkyl, or O—C1-4-alkyl; R2 is hydrogen, halogen, C1-4-alkyl, or O—C1-4-alkyl; and R3 is hydrogen, C1-4-alkyl, OH, halogen, O—C1-4-alkyl, O—C1-4-alkylene-COOH, or O—C14-alkylene-COO—C1-4-alkyl, or an enantiomer, mixture of enantiomers, or racemate thereof, or an acid addition salt with pharmacologically acceptable acids thereof, or a solvate or hydrate thereof; and (b) another active substance 2, wherein the molar ratio of the compound of formula 1 to the active substance 2 is 1:10 to 12:1.
    Type: Application
    Filed: December 3, 2014
    Publication date: March 26, 2015
    Inventors: Thierry BOUYSSOU, Michael Paul PIEPER, Andreas SCHNAPP
  • Patent number: 8986658
    Abstract: The present invention related to the use of a pharmaceutical composition which is essentially free of pharmaceutically active ingredients for the treatment of human skin, especially in the treatment of rosacea, acne, atopic dermatitis, contact dermatitis, perioral dermatitis, psoriasis or neurodermitis, as well as for prophylactic and/or cosmetic purposes.
    Type: Grant
    Filed: December 27, 2013
    Date of Patent: March 24, 2015
    Assignee: Intendis GmbH
    Inventors: Klaus Graupe, Gerald Stadtler
  • Patent number: 8986738
    Abstract: A medical aid for the direct transport of at least one drug into lung regions of a patient, wherein provided as the carrier for at least one active substance is at least one semifluorinated alkane in which the at least one active substance is purely physically dissolved in a homogeneous phase.
    Type: Grant
    Filed: March 31, 2009
    Date of Patent: March 24, 2015
    Assignee: NOVALIQ GmbH
    Inventor: Hasso Meinert
  • Publication number: 20150079185
    Abstract: The invention relates to a method for making composite active particles for use in a pharmaceutical composition for pulmonary administration, the method comprising a milling step in which particles of active material are milled in the presence of particles of an additive material which is suitable for the promotion of the dispersal of the composite active particles upon actuation of an inhaler. The invention also relates to compositions for inhalation prepared by the method.
    Type: Application
    Filed: November 25, 2014
    Publication date: March 19, 2015
    Inventors: JOHN NICHOLAS STANIFORTH, MATTHEW MICHAEL GREEN, DAVID ALEXANDER VODDEN MORTON
  • Patent number: 8980228
    Abstract: The present invention relates, e.g., to a system for treating damaged skin, comprising a cosmeceutical formulation comprising about 1-10% of a mixture of perfluorocarbons (PFC's) of at least three different molecular weights, and about 0.001-5% hyaluronic acid (HA) of molecular weight about 100 kDa or less, packaged in an aerosol spray container.
    Type: Grant
    Filed: March 4, 2013
    Date of Patent: March 17, 2015
    Assignee: Kate Somerville Skincare, LLC
    Inventors: Kate Somerville, Fred Khoury
  • Patent number: 8980227
    Abstract: The present invention relates, e.g., to a system for treating damaged skin, comprising a cosmeceutical formulation comprising about 1-10% of a mixture of perfluorocarbons (PFC's) of at least three different molecular weights, and about 0.001-5% hyaluronic acid (HA) of molecular weight about 100 kDa or less, packaged in an aerosol spray container.
    Type: Grant
    Filed: August 16, 2012
    Date of Patent: March 17, 2015
    Assignee: Kate Somerville Skincare, LLC
    Inventors: Kate Somerville, Fred Khoury
  • Patent number: 8980226
    Abstract: A fosfomycin plus tobramycin combination formulation for delivery by aerosolization is described. The concentrated fosfomycin tobramycin combination formulation containing an efficacious amount of fosfomycin plus tobramycin is able to inhibit susceptible bacteria. Fosfomycin and tobramycin are formulated separately in a dual ampoule such that when reconstituted, the pH is between 4.5 and 8.0 or as a dry powder. The method for treatment of respiratory tract infections by a formulation delivered as an aerosol having mass median aerodynamic diameter predominantly between 1 to 5?, produced by a jet or ultrasonic nebulizer (or equivalent) or dry powder inhaler.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: March 17, 2015
    Assignee: Gilead Sciences, Inc.
    Inventors: William Baker, David MacLeod
  • Patent number: 8974771
    Abstract: This disclosure relates to an apparatus useful for the delivery of aerosols, such as those containing drugs, to the lungs or other locations in the body. The disclosure also relates to methods of administering an aerosol to the lungs or other locations in the body of a patient.
    Type: Grant
    Filed: March 9, 2010
    Date of Patent: March 10, 2015
    Assignee: Penn-Century, Inc.
    Inventor: Theodore J. Century
  • Patent number: 8940321
    Abstract: The present invention relates to compositions and methods useful for the treatment of ear disorders, administered to a treated ear in the form of a foam or a mousse. Administering a medicament in such forms will increase the residence time of the medicament in the ear canal, provide relatively uniform distribution of the composition, and can increase the penetration of the active pharmaceutical ingredient in the affected area, may release active substances slowly, enhance treatment effectiveness, increase compliance and is more convenient to use than currently available ear medications. The administration in the form of a foam or a mousse may preferably be provided as a metered dose, of a volume suitable to fill the ear canal.
    Type: Grant
    Filed: April 2, 2012
    Date of Patent: January 27, 2015
    Assignee: Otic Pharma Ltd.
    Inventor: Eran Eilat
  • Patent number: 8940271
    Abstract: The invention includes compositions for transmucosal administration to an animal comprising at least one active agent and a pharmaceutically acceptable carrier. A preferred active agent is selected from the group consisting of meloxicam, carprofen, enrofloxacin, clemastine, diphenhydramine, digoxin, levothyroxine, cyclosporine, ondansetron, lysine, zolpidem, propofol, nitenpyram, ivermectin, milbemycin, and pharmaceutically acceptable salts, solvates and esters thereof. In another embodiment, the invention includes methods of treating or preventing a condition in an animal comprising transmucosally administering a composition comprising a therapeutically or prophylactically effective amount of an active agent and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: December 15, 2011
    Date of Patent: January 27, 2015
    Assignee: Abbott Laboratories
    Inventors: Mark C. Heit, Antonio M. Benitz, Dennis F. Steadman, David M. Petrick
  • Patent number: 8940319
    Abstract: The present invention is directed to compositions, devices, and methods for non-irritatively treating and preventing mucositis, such as chronic rhinosinusitis (CRS). Some aspects of the invention concern compositions comprising or consisting essentially of sodium phosphate buffer (e.g., sodium phosphate dibasic and sodium phosphate monobasic) and calcium carbonate; mucoadministration devices and kits containing such compositions; and methods for treating or preventing mucositis conditions such as CRS, comprising mucoadministering a composition of the invention to a subject in need thereof.
    Type: Grant
    Filed: June 1, 2012
    Date of Patent: January 27, 2015
    Assignee: Accentia Biopharmceuticals, Inc.
    Inventors: Francis E. O'Donnell, Angelos M. Stergiou
  • Publication number: 20150023888
    Abstract: The invention is drawn to a novel, early interventional use of a pharmaceutical composition wherein administration of said pharmaceutical composition pre-empts the onset of migraine headaches, preferably anytime in the migraine cycle prior to pain onset. The pharmaceutical composition preferably is administered via inhalation in order to provide therapy to the subject in a timely fashion, ideally in a non-clinical setting. The pharmaceutical composition may also be administered to a subject at risk for stroke.
    Type: Application
    Filed: September 30, 2014
    Publication date: January 22, 2015
    Inventors: ROBERT O. COOK, PAUL L. DURHAM
  • Publication number: 20150017104
    Abstract: Compositions, methods and systems are provided for pulmonary or nasal delivery of two or more active agents via a metered dose inhaler. In one embodiment, the compositions include a suspension medium, active agent particles, and suspending particles, in which the active agent particles and suspending particles form a co-suspension within the suspension medium.
    Type: Application
    Filed: July 17, 2014
    Publication date: January 15, 2015
    Inventors: Reinhard Vehring, Michael Steven Hartman, David Lechuga-Ballesteros, Adrian Edward Smith, Vidya B. Joshi, Sarvajna Kumar Dwivedi
  • Publication number: 20150017247
    Abstract: Compositions, methods and systems are provided for pulmonary delivery of long-acting muscarinic antagonists and long-acting ?2 adrenergic receptor agonists via a metered dose inhaler. In particular embodiments, the compositions include a suspension medium, active agent particles, and suspending particles, in which the active agent particles and suspending particles form a co-suspension within the suspension medium.
    Type: Application
    Filed: July 9, 2014
    Publication date: January 15, 2015
    Inventors: Reinhard Vehring, Michael Steven Hartman, Adrian Edward Smith, Vidya B. Joshi, Sarvajna Kumar Dwivedi
  • Publication number: 20150017103
    Abstract: The present invention relates to a waterless composition and foam as a vehicle in which an active pharmaceutical or cosmetic agent, when added is stable or stabilized by or its destabilization is impeded by the presence of a modulating agent. The pharmaceutical or cosmetic composition and foam, includes: a waterless solvent, a modulating agent and one or more active pharmaceutical or cosmetic agents. The present invention also relates to a method of treatment administering the waterless composition and foam.
    Type: Application
    Filed: October 3, 2013
    Publication date: January 15, 2015
    Applicant: Foamix Ltd.
    Inventors: Dov Tamarkin, Meir Eini, Doron Friedman, Tal Berman, David Schuz
  • Patent number: 8927474
    Abstract: An aqueous compressed gas aerosol formulation in combination with a lined steel can, which may also optionally be tin plated, to provide corrosion stability, fragrance stability and color stability. An aerosol formulation of particular advantage for use is an air and/or fabric treatment formulation. The combination provides a compatibility which allows for the ability to use a broader fragrance pallet for the air and/or fabric treatment formulation which is aqueous based in major proportion. The formulation includes, in addition to an aqueous carrier, a fragrance, nonionic surfactant(s) or a blend of nonionic surfactant(s) and cationic surfactant(s), a compressed gas propellant(s), pH adjuster(s), and corrosion inhibitor(s). The formulation has a pH of about 8 to less than 10. The corrosion inhibitor(s) is(are) mild in strength and used in a minor amount.
    Type: Grant
    Filed: March 16, 2012
    Date of Patent: January 6, 2015
    Assignee: S.C. Johnson & Son, Inc.
    Inventor: Bhaveshkumar Shah
  • Publication number: 20140377365
    Abstract: Provided herein are methods and compositions for producing formulations systemic delivery of dopamine agonists via the oral inhalation route. Specifically, provided herein are methods and compositions for a formulation of rotigotine that is suitable for administration via oral inhalation. Such methods and compositions are useful in the treatment or amelioration of one or more Parkinson's disease symptom(s).
    Type: Application
    Filed: June 18, 2014
    Publication date: December 25, 2014
    Inventors: Libo WU, Wiwik WATANABE
  • Publication number: 20140377189
    Abstract: Provided herein are methods and compositions for producing formulations systemic delivery of dopamine agonists via the oral inhalation route. Specifically, provided herein are methods and compositions for a stable solution formulation of rotigotine that is suitable for administration via oral inhalation. Such methods and compositions are useful in the treatment or amelioration of one or more Parkinson's disease symptom(s).
    Type: Application
    Filed: June 18, 2014
    Publication date: December 25, 2014
    Inventors: Libo WU, Wiwik WATANABE
  • Patent number: 8911711
    Abstract: Methods, devices, and systems are provided which include an aerosol generator and a pharmaceutical composition including a membrane selective for a charged ion configured to achieve a selected pH of a pulmonary tissue in a subject. The methods, devices, or systems which include the membrane may be configured to alter selectivity for the charged ion in response to a sensed condition in the pulmonary tissue.
    Type: Grant
    Filed: September 30, 2008
    Date of Patent: December 16, 2014
    Assignee: The Invention Science Fund I, LLC
    Inventors: Roderick A. Hyde, Muriel Y. Ishikawa, Jordin T. Kare, Dennis J. Rivet, Lowell L. Wood, Jr., Victoria Y. H. Wood